Coalition for Epidemic Preparedness Innovations
VC Fund
Washington, United States
Coalition for Epidemic Preparedness Innovations is a VC fund in Washington focused on Biotechnology and Health Care. The Coalition for Epidemic Preparedness Innovations (CEPI) is a non profit organisation. CEPI wants to galvanise the development of new vaccines against diseases we know could cause the next devastating epidemic.
- Total investments:
- 42
- Last investment:
- Lead investor:
- 95%
Last updated:
For AI agents: llms.txt
Industries Coalition for Epidemic Preparedness Innovations invests in
Stages Coalition for Epidemic Preparedness Innovations invests in
Countries Coalition for Epidemic Preparedness Innovations invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Round size
- Grant
- $3.2M–$42M
- Post-IPO Equity
- $2.5M–$145M
Investment Focus
Industry
- Biotechnology 26 (62%)
- Health Care 19 (45%)
- Pharmaceutical 14 (33%)
- Medical 10 (24%)
- Life Science 7 (17%)
Stage
- Grant 28 (67%)
- Post-IPO Equity 3 (7%)
- Seed 2 (5%)
- Funding Round 1 (2%)
- Post-IPO Debt 1 (2%)
Country
- United States 15 (36%)
- India 4 (10%)
- United Kingdom 3 (7%)
- France 2 (5%)
- China 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Malika Almansouri
Regulatory Affairs
|
Regulatory Affairs | Total investments: 0 | Find email | |
Renske Hesselink
Senior Scientist CMC
|
Senior Scientist CMC | Total investments: 0 | Find email | |
|
Anand Ekambaram
Executive Director
|
Executive Director | Total investments: 1 | Find email | |
Frederik Kristensen
Deputy CEO
|
Deputy CEO | Total investments: 0 | Find email | |
Nicholas Jackson
Head of Programs and Innovation, R&D
|
Head of Programs and Innovation, R&D | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| MINAPHARM is constantly striving to provide innovative quality medicines and services to patients in developing countries so they, too, can get a timely benefit from the latest advances in pharmaceutical and biopharmaceutical research technologies. To achieve its mission and strategic goals, MINAPHARM exploits a robust research and developmentplatform combined with strategic multi-alliances involving industry players at the forefront of the latest pharmaceutical technologies, marketing and management techniques. This way has further enabled the establishment of specialized lines, embracing innovative and affordable products and services in the fields of Gastroenterology, Cardiology, Ophthalmology, Orthopedics, and Uro-gynaecology. | $16.5M / Grant / Aug 27, 2026 | ||
| Hilleman Laboratories is a non-profit and global welfare organization proprietor of a research and vaccine organization created to fill gaps in reduced environments. By utilizing advanced biotechnology with a focus on thermo-stability, ease of administration decreased footprint and economy, the firm aims to develop an innovative vaccinationplatform and offer affordable vaccines for unusual diseases to the general public. | $8.5M / Grant / Jul 30, 2026 | ||
| POP Biotechnologies is a Buffalo, NY, life sciences company committed to improving the health of individuals with next-generation nanomedicine solutions | $9.7M / Grant / Jun 03, 2026 | ||
| Moderna is a biotechnology company that develops medicines and vaccines based on messenger RNA (mRNA) technology. Moderna designs mRNA molecules that instruct cells to produce specific proteins, with applications in the prevention and treatment of a range of diseases. Its research and development activities span infectious diseases, cancer, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna maintains a pipeline of vaccine and therapeutic candidates and utilizes a platform approach that combines mRNA design, delivery technologies, and manufacturing processes across multiple programs. The company also collaborates with research institutions, healthcare organizations, and industry partners to the development of its mRNA-based medicines. | $50M / Grant / Jun 01, 2026 | ||
| Oxford is a collegiate university, consisting of the central University and colleges. The central University is composed of academic departments and research centers, administrative departments, libraries, and museums. The 38 colleges are self-governing and financially independent institutions, which are related to the central University in a federal system. There are also six permanent private halls, which were founded by different Christian denominations and which still retain their Christian character. The collegiate system is at the heart of the University’s success, giving students and academics the benefits of belonging both to a large, internationally renowned institution and to a small, interdisciplinary academic community. It brings together leading academics and students across subjects and year groups and from different cultures and countries, helping to foster the intense interdisciplinary approach that inspires much of the outstanding research. | $8.6M / Grant / Jun 01, 2026 | ||
| International AIDS Vaccine Initiative is a not-for-profit organization which ensure use of preventive HIV vaccines throughout the world. | $3.2M / Grant / Jun 01, 2026 | ||
| Alveo Technologies is changing the world by applying cutting edge advances in sensing, microfluidics, and bioassays to create the next-generation of disease and personal care diagnostic devices.Their innovative products connect and empower consumers, healthcare professionals and treatment providers with the ability to know sooner, act faster, andmake better-informed decisions. Advanced diagnostics clear the path to more personalized medicine and better outcomes. | $200K / Grant / May 26, 2026 | ||
|
Analysis Zero
|
Analysis Zero is in stealth mode. | Seed / Apr 16, 2026 | |
| Centivax is a healthcare-based agency that provides biotechnology, pharmaceutical, medical device manufacturing, and therapeutic services. | $26M / Grant / Feb 12, 2026 | ||
| Moderna is a biotechnology company that develops medicines and vaccines based on messenger RNA (mRNA) technology. Moderna designs mRNA molecules that instruct cells to produce specific proteins, with applications in the prevention and treatment of a range of diseases. Its research and development activities span infectious diseases, cancer, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna maintains a pipeline of vaccine and therapeutic candidates and utilizes a platform approach that combines mRNA design, delivery technologies, and manufacturing processes across multiple programs. The company also collaborates with research institutions, healthcare organizations, and industry partners to the development of its mRNA-based medicines. | $54.3M / Grant / Dec 18, 2025 | ||
| See all 42 investments → | |||
Co-Investors
Bill & Melinda Gates Foundation
2 deals together
Horizon Europe
2 deals together
Military Infectious Diseases Research Program
1 deal together
National Institutes of Health
1 deal together
United States Navy Bureau of Medicine and Surgery
1 deal together
U.S. Department of Agriculture
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Coalition for Epidemic Preparedness Innovations invest in?
Coalition for Epidemic Preparedness Innovations invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Grant and Post-IPO Equity stage. Most of the 42 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Coalition for Epidemic Preparedness Innovations invest in?
Coalition for Epidemic Preparedness Innovations typically joins rounds of $3.2M–$42M at Grant and $2.5M–$145M at Post-IPO Equity. These are whole funding-round sizes, not Coalition for Epidemic Preparedness Innovations's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Coalition for Epidemic Preparedness Innovations took part in.
How do I contact Coalition for Epidemic Preparedness Innovations?
Public channels for Coalition for Epidemic Preparedness Innovations include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Coalition for Epidemic Preparedness Innovations?
The team at Coalition for Epidemic Preparedness Innovations includes Malika Almansouri (Regulatory Affairs), Renske Hesselink (Senior Scientist CMC) and Anand Ekambaram (Executive Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
